文献速递皮肤肿瘤

葡萄膜黑色素瘤与皮肤黑色素瘤中BCL2家族成员表达差异导致对BH3模拟物敏感性不同

Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics.
PubMed 文献 · J Invest Dermatol · 2021-12-20

研究比较葡萄膜黑色素瘤(UM)与皮肤黑色素瘤(CM)的BCL2家族成员表达,发现UM具有低BFL1和高PUMA的独特表达特征,对MCL1抑制剂(MCL1i)敏感性高于CM。过表达BFL1或敲低PUMA使UM对MCL1i更耐药;CM经MAPK/ERK抑制剂处理后对MCL1i更敏感。MCL1i单药减少UM起始细胞效果有限,与BCL2抑制剂联用可协同抑制UM起始细胞扩增。

要点

  • UM相比CM及30种其他癌种具有低BFL1和高PUMA的BCL2家族表达特征。
  • UM对MCL1i的敏感性高于CM;过表达BFL1或敲低PUMA增加UM对MCL1i的耐药性。
  • MCL1i与BCL2抑制剂联用协同抑制UM起始细胞扩增,单用MCL1i效果有限。

核心结论

  • UM具有独特的BCL2家族成员表达谱,使其对BH3模拟物敏感;MCL1i与BCL2抑制剂联用可协同抑制UM起始细胞扩增。

研究设计与样本

  • 采用免疫印迹和癌症基因组图谱(TCGA)转录组分析比较UM与CM的BCL2家族成员表达。
  • 在UM中通过活力检测、活细胞成像、球体实验和小鼠异种移植模型测试BCL2抑制剂和MCL1抑制剂(MCL1i)的疗效。

主要发现

  • UM相比CM及30种其他癌种具有低BFL1和高PUMA蛋白的独特特征。
  • UM对MCL1i的敏感性高于CM。
  • 过表达BFL1或敲低PUMA使UM对MCL1i更耐药。
  • CM经MAPK/细胞外信号调节激酶抑制剂处理后对MCL1i更敏感。
  • MCL1i单药减少UM起始细胞效果有限;MCL1i与BCL2抑制剂联用协同抑制UM起始细胞扩增。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Uveal melanoma (UM) is a subtype of melanoma. Although they share a melanocytic origin with cutaneous melanoma (CM), patients with UM have few treatment options. BCL2 homologous 3 mimetics are small-molecule drugs that mimic proapoptotic BCL2 family members. We compared BCL2 family member expression between UM and CM using immunoblot and The Cancer Genome Atlas transcriptomic analysis. UM has a unique signature of low BFL1 and high PUMA proteins compared with CM and 30 other cancer types, making them an attractive candidate for BCL2 homologous 3 protein mimetics. We tested the efficacy of a BCL2 inhibitor and MCL1 inhibitor (MCL1i) in UM, with viability assays, live-cell imaging, sphere assays, and mouse xenograft models. UM had a higher sensitivity to MCL1i than CM. Overexpression of BFL1 or knockdown of PUMA made the UM more resistant to MCL1i. In contrast, MAPK/extracellular signal‒regulated kinase inhibitor treatment in CM made them more sensitive to MCL1i. However, MCL1i-alone treatment was not very effective to reduce the UM initiating cells; to overcome this, we employed a combination of MCL1i with BCL2 inhibitor that synergistically inhibited UM initiating cell's capacity to expand. Overall, we identify a distinct expression profile of BCL2 family members for UM that makes them susceptible to BCL2 homologous 3 mimetics.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Mukherjee N, Dart CR, Amato CM, et al. Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics. J Invest Dermatol. 2021. PMID: 34942200. doi:10.1016/j.jid.2021.11.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。